
Australian Dentists Endorse Smartee's Mandibular Repositioning Technology at Global Symposium in Kunming
KUNMING, China, July 11, 2025 /PRNewswire/ -- Smartee Denti-Technology recently welcomed orthodontic experts and partners from Australia at its Global Symposium in Kunming, China. The event offered a deep dive into Smartee's Mandibular Repositioning Technology and showcased its clinical applications, particularly the innovative S8-SGTB appliance for Class II skeletal malocclusions. Australian clinicians praised the device for its simultaneous orthopedic and orthodontic correction, shorter treatment duration, and patient-friendly design.
Dr. Knox Kim, Principal Dentist at Dental Clinic @ World Tower Sydney, shared:
"In the past, for treating Class II malocclusions in growing patients, we had to use twin-block appliances before starting aligner therapy. It took at least three to six months to see the improvement. But with Smartee, from my own experience, it only took about one or two weeks before the patient could notice the lower jaw was pushing forward. And when I show the patients and the patients' parents the before and after photos, they were very happy to see such a quick response and improvement."
Dr. Jenny J. Song from Blossom Dental Care added:
"Compared to traditional functional and fixed appliances, Smartee GS is intelligently designed to guide both mandible repositioning and teeth movement simultaneously. This not only reduces total treatment time but also improves the predictability of outcomes."
Dr. Sabrina Liu, a general dentist in Sydney, reflected:
"This seminar was eye-opening. The number of successful mandibular repositioning cases using Smartee GS aligners changed my perception of what clear aligners can achieve. I hope more dentists in Australia will learn about this technique to benefit their patients."
At the core of Smartee's Mandibular Repositioning Technology is S8-SGTB, a clear, non-invasive appliance designed to treat skeletal Class II discrepancies, minimizing the need for jaw surgeries or extractions. Engineered for both growing and adult patients, it integrates orthopedic and orthodontic functions in a single aligner-based solution.
Key features include:
The S8-SGTB represents Smartee's commitment to delivering clinically effective, patient-centered treatment paths for complex cases.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Korea Herald
3 days ago
- Korea Herald
Australian Dentists Endorse Smartee's Mandibular Repositioning Technology at Global Symposium in Kunming
Clinicians praise the S8-SGTB appliance for accelerating outcomes, improving patient satisfaction, and offering a non-invasive solution for Class II malocclusions. KUNMING, China, July 11, 2025 /PRNewswire/ -- Smartee Denti-Technology recently welcomed orthodontic experts and partners from Australia at its Global Symposium in Kunming, China. The event offered a deep dive into Smartee's Mandibular Repositioning Technology and showcased its clinical applications, particularly the innovative S8-SGTB appliance for Class II skeletal malocclusions. Australian clinicians praised the device for its simultaneous orthopedic and orthodontic correction, shorter treatment duration, and patient-friendly design. Dr. Knox Kim, Principal Dentist at Dental Clinic @ World Tower Sydney, shared: "In the past, for treating Class II malocclusions in growing patients, we had to use twin-block appliances before starting aligner therapy. It took at least three to six months to see the improvement. But with Smartee, from my own experience, it only took about one or two weeks before the patient could notice the lower jaw was pushing forward. And when I show the patients and the patients' parents the before and after photos, they were very happy to see such a quick response and improvement." Dr. Jenny J. Song from Blossom Dental Care added: "Compared to traditional functional and fixed appliances, Smartee GS is intelligently designed to guide both mandible repositioning and teeth movement simultaneously. This not only reduces total treatment time but also improves the predictability of outcomes." Dr. Sabrina Liu, a general dentist in Sydney, reflected: "This seminar was eye-opening. The number of successful mandibular repositioning cases using Smartee GS aligners changed my perception of what clear aligners can achieve. I hope more dentists in Australia will learn about this technique to benefit their patients." At the core of Smartee's Mandibular Repositioning Technology is S8-SGTB, a clear, non-invasive appliance designed to treat skeletal Class II discrepancies, minimizing the need for jaw surgeries or extractions. Engineered for both growing and adult patients, it integrates orthopedic and orthodontic functions in a single aligner-based solution. Key features include: The S8-SGTB represents Smartee's commitment to delivering clinically effective, patient-centered treatment paths for complex cases.

Korea Herald
4 days ago
- Korea Herald
LG Debuts Next-Generation Precision Medical AI
Joint Development Underway: World-Class Precision Medical AI Platform with Vanderbilt University Medical Center SEOUL, South Korea, July 10, 2025 /PRNewswire/ -- LG AI Research announced on July 9 the official launch of 'EXAONE Path 2.0', its next-generation precision medical AI model. Following the introduction of its 1.0 model in August of last year, LG AI Research showcased its 1.5 model last month at ASCO 2025, the world's largest oncology conference, held in Chicago, Illinois. 'EXAONE Path 2.0' represents a substantial advancement from the initial version, incorporating high-quality, real-world data. It offers accurate characterization and prediction of gene mutations and expression profiles, as well as minute morphological and structural features of human cells and tissues, all derived directly from pathology slide images. These capabilities make it an essential tool for early detection, prognosis, oncology drug development, and personalized treatment selection. 'EXAONE Path 2.0' was trained using multi-omics data, including both DNA and RNA, enabling it to interpret pathology images and underlying biological processes while integrating genetic insights vital to disease research and therapeutic development. Pathology images refer to high-resolution Whole Slide Images (WSIs) generated during the diagnostic test of patient tissue specimens. Whole Slide Images (WSIs) are large, multi-gigabyte digital files that capture detailed information on cell and tissue architecture. To facilitate analysis, these comprehensive images are typically divided into thousands of smaller sub-images or "patches." When AI models analyze only patch-level data, they are susceptible to a "feature collapse" effect, in which excessive attention to localized features leads to reduced prediction accuracy due to a lack of holistic context. LG AI Research has implemented an innovative approach in 'EXAONE Path 2.0', enabling learning from individual patches through to the full Whole Slide Image. This enhancement has increased the model's gene mutation prediction accuracy to a best-in-class 78.4%, establishing a new State-of-the-Art (SOTA) benchmark. 'EXAONE Path 2.0' was developed using over 10,000 matched datasets comprising Whole Slide Images and multi-omics data. This robust training enables it to predict gene expression patterns solely from image analysis, eliminating the need for expensive molecular testing. Yong-min Park, Head of AI Business Team at LG AI Research, stated, "EXAONE Path 2.0 enables us to reduce molecular testing time from over two weeks to under a minute—helping clinicians capture critical therapeutic windows for cancer patients. By leveraging EXAONE Path 2.0, physicians and pharmaceutical partners can rapidly analyze tissue pathology slides, identify driver mutations, and select appropriate targeted therapies." LG AI Research also introduced additional models trained for specific tumor types, including lung and colorectal cancers. These disease-specific models may support more efficient triaging and early detection of patients eligible for targeted therapeutic interventions. LG AI Research expects 'EXAONE Path 2.0' to play a significant role in clinical trial optimization by enabling real-time monitoring of patient responses and facilitating biomarker discovery for disease prediction. LG AI Research has taken a major step forward in applying AI to cancer care. In collaboration with Professor Tae-hyun Hwang of Vanderbilt University Medical Center—a premier U.S. academic medical institution in biomedical research—LG AI Research is co-developing a cutting-edge multi-modal medical AI platform. Moving away from the conventional model of building technologies prior to clinical validation, the team has adopted a problem-first approach—developing AI solutions in tandem with real-world clinical needs. Together, LG AI Research and Professor Hwang's lab aim to build a platform that supports personalized precision medicine, utilizing real tissue samples, pathology images, and clinical outcome data from cancer patients enrolled in trials. Their joint research will focus on: Professor Tae-hyun Hwang noted, " Our mission goes beyond developing AI models—we are building a platform that actively supports clinicians in the care and treatment of patients. This platform will serve not just as a diagnostic assistant but as a transformative engine for oncology drug development." Professor Hwang is a renowned Korean-American expert leading the Cancer Moonshot's gastric cancer initiative, a U.S. federal program dedicated to accelerating cancer breakthroughs. He also founded the Molecular AI Initiative at Vanderbilt, focused on advancing AI-integrated molecular medicine. "We're now focused on identifying not just what treatments work but when and how to apply them," said Seth Karp, Chair of the Section of Surgical Sciences at Vanderbilt University Medical Center. "The collaboration between LG AI Research and Professor Hwang's team marks a critical inflection point. The most meaningful aspect of this partnership is its real-world impact—we are creating a platform that will directly support patient care and improve outcomes." Beginning with oncology, the LG AI Research–Vanderbilt collaboration plans to expand into other domains including transplant immunology, autoimmune diseases, and metabolic disorders such as diabetes. LG AI Research will formally introduce 'EXAONE Path 2.0' during the upcoming LG AI Talk Concert 2025 on July 22. Separately, LG AI Research remains committed to addressing high-burden diseases. It is collaborating with The Jackson Laboratory (JAX) to identify Alzheimer's disease risk factors and advance drug discovery, and is also working with Professor Min-kyung Baek of Seoul National University on AI models for next-generation protein structure prediction. Furthermore, LG AI Research is actively engaged in global partnerships with pharmaceutical and biotech firms to drive innovation in AI-based drug development. LG Corporation Chairman and CEO Kwang-mo Koo has identified AI and biotechnology as strategic growth areas central to improving human health. Reflecting this vision, LG is accelerating efforts in AI–bio convergence through targeted open innovation initiatives aimed at delivering tangible results. About LG Group LG Group is a leading global company representing South Korea, offering innovative products and services across various industries such as electronics, chemicals, telecommunications, and energy. Established in 1947, LG Group has grown into a world-renowned brand through its activities in these diverse fields. The company is committed to continuous research and development, focusing on innovation to enhance the quality of life for its customers. Emphasizing its role as a socially responsible enterprise, LG Group is striving to strengthen its competitiveness in the global market and achieve sustainable growth through its future portfolio in areas like AI, Bio, and Cleantech. The company is dedicated to realizing its vision of being a business that provides value to customers and society, pursuing this mission with unwavering determination. For more information, visit About LG AI Research Launched in December 2020 as the artificial intelligence (AI) research hub of South Korea's LG Group, LG AI Research aims to lead the next epoch of artificial intelligence (AI) to realize a promising future by providing optimal research environments and leveraging state-of-the-art AI technologies. And LG AI Research developed its large-scale AI, EXAONE, a 300 billion parametric multimodal AI model, in 2021. EXAONE, which stands for "Expert AI for Everyone," is a multi-modal large-scale AI model that stands out from its peers due to its ability to process both language and visual data. With one of the world's largest learning data capacities, LG AI Research aims to engineer better business decisions through its state-of-the-art artificial intelligence technologies and its continuous effort on fundamental AI research. For more information, visit About Vanderbilt University Medical Center Vanderbilt University Medical Center (VUMC) is one of the nation's leading academic medical centers, dedicated to advancing healthcare through pioneering research, high-impact education, and exceptional patient care. Based in Nashville, Tennessee, VUMC provides comprehensive services across every major clinical specialty and serves as a regional and national referral center for complex conditions. VUMC is a hub for innovation in translational medicine, biomedical informatics, genomics, and AI-driven healthcare. Its close integration with Vanderbilt University enables seamless collaboration across disciplines, accelerating the development of next-generation diagnostics, therapeutics, and digital health solutions. VUMC is home to nationally recognized programs in cancer, cardiovascular disease, neurosciences, transplantation, and surgical innovation, and is committed to bringing cutting-edge discoveries from bench to bedside. For more information, visit


Korea Herald
6 days ago
- Korea Herald
Zuellig Pharma Launches "Obesity is a Disease" Seminar as Part of "Reduce Size, Reduce Disease" Campaign
The campaign aims to enhance the understanding of obesity as a chronic disease and solutions to help manage the disease among Thais and healthcare providers. BANGKOK, July 8, 2025 /PRNewswire/ -- Zuellig Pharma, a leading healthcare solutions provider in Asia, is organizing the "Obesity is a Disease" seminar as part of its "Reduce Size, Reduce Disease" awareness campaign. The seminar aims to reinforce the message that obesity is more than a cosmetic concern, and solutions to manage the disease among healthcare practitioners. It is a silent national public health crisis that significantly impacts individuals living with obesity, particularly women. Studies have highlighted the urgency of addressing rising obesity rates, as the 2014 National Health Examination Survey found that 37.5% of Thais aged 15 and over were obese (BMI > 25), with the rate for women at 41.8%. By 2023, this figure had climbed to 45% for women, compared to 38% for men 1. Women with obesity face an increased risk of serious health conditions, including Polycystic Ovary Syndrome (PCOS), uterine problems, infertility, breast and endometrial cancer. The "Reduce Size, Reduce Disease" campaign therefore aims not only to encourage behavioral change but also to dismantle the social stigma that treats obesity as a personal failure, fostering an understanding of it as a chronic disease that requires proper care. Ms. Sunaiyanaa Kidkasetpaisal, Zuellig Pharma's General Manager for Commercialization in Thailand, said, "Zuellig Pharma is dedicated to enhancing the health of the Thai people by championing the understanding that obesity is not about aesthetics, and instead is a chronic disease requiring holistic treatment. We believe that equitable access to healthcare is the foundation of a sustainable society, and our 'Reduce Size, Reduce Disease' campaign is a direct reflection of this commitment, moving beyond promoting new treatment innovations to providing comprehensive knowledge and practical guidance on weight management. This seminar reflects our dedication in driving change and shifting the societal narrative on obesity from judgment to understanding and care, for the long-term health for everyone." The "Obesity is a Disease" seminar involved healthcare practitioners from all over Thailand, who are committed to educating and deepening their understanding of obesity as a disease among Thais; and constantly find ways and solutions to help fight the disease. Prof. Dr. Rungsima Wanitphakdeedecha, Head of the Department of Dermatology, Chief of the Division of Dermatologic Surgery, and Director of the Siriraj Skin Laser Center at the Faculty of Medicine Siriraj Hospital, Mahidol University, explained, "At its heart, the "Reduce Size, Reduce Disease" campaign is about inspiring people in Thailand to embrace a holistic approach to their well-being, focusing on safe and effective health management to prevent comorbidities linked to obesity. It shows that when we truly invest in our own well-being, long-term health will be sustainable." Asst. Prof. Dr. Mart Maiprasert, Dean and Chairman of the Graduate Program Executive Committee at the College of Integrative Medicine (CIM), said "Effective weight management today hinges on multiple factors, including a strong partnership between patients and medical experts, proper lifestyle habits, good nutrition, and consistent exercise. Together, these elements form the foundation of what we call the 'X2' approach, which emphasizes that being healthy is not achieved through dieting or exercise alone but through a sustainable, balanced integration of both for lasting results." Master Dr. Rassapoom Sumaetheiwit, a specialist in dermatology and aesthetic medicine, added, "Helping our clients with effective body composition management is not just a series of procedures, but an art grounded in medical science, demanding a deep, individual understanding of each patient to tailor the most appropriate and safe treatment plan. This integrated approach ensures that losing weight is not merely about aesthetics, but about achieving genuine health and physical balance. Our commitment is to provide this level of comprehensive, personalized care to deliver safe and sustainable long-term results." The "Reduce Size, Reduce Disease" project aims to raise awareness that "Obesity is a disease" requiring medical attention, while also spotlighting the urgent public health challenge that obesity represents in Thailand. About Zuellig Pharma Zuellig Pharma is a leading healthcare solutions company in Asia, and our purpose is to make healthcare more accessible to the communities we serve. We provide world-class distribution, digital and commercial services to support the growing healthcare needs in this region. The company was started a hundred years ago and has grown to become a multibillion-dollar business covering 17 markets with over 12,000 employees. Our people serve more than 200,000 medical facilities and work with over 450 clients, including the top 20 pharmaceutical companies in the world.